Streptococcus pneumoniae capsular polysaccharide-protein conjugate (PCV) (PCV)

Streptococcus pneumoniae capsular polysaccharide-protein conjugates are the active antigenic components of pneumococcal conjugate vaccines (PCVs) (CDC, 2024). These molecules consist of purified capsular polysaccharides from specific S. pneumoniae serotypes that are chemically linked to a carrier protein, most commonly CRM197 (a non-toxic mutant of diphtheria toxin) or tetanus toxoid (FDA, 2023). The primary biological function of this conjugation is to overcome the limitations of pure polysaccharide antigens, which are T-cell independent and poorly immunogenic in children under two years of age (Pollard et al., 2009). By linking the polysaccharide to a protein, the immune system can process the complex via the T-cell dependent pathway, involving MHC class II presentation to T-helper cells (WHO, 2021). This process induces high-affinity IgG antibodies, mucosal immunity, and long-term immunological memory. These conjugates are used to prevent a range of pneumococcal diseases, including invasive infections like meningitis and bacteremia, as well as non-invasive conditions like pneumonia and otitis media (StatPearls, 2023). The development of these targets has significantly reduced the global burden of pneumococcal disease, although serotype replacement remains a challenge for vaccine design (CDC, 2024).

Other names

Pneumococcal conjugate vaccineS. pneumoniae polysaccharide conjugateCRM197-conjugated pneumococcal polysaccharidePneumococcal polysaccharide-protein conjugatePCV13PCV15PCV20PCV21

The mechanism involves the conversion of T-cell independent polysaccharide antigens into T-cell dependent antigens. Upon administration, the conjugate is internalized by B-cells or other antigen-presenting cells; the protein carrier is then proteolytically processed and presented via MHC class II molecules to CD4+ T-helper cells (Pollard et al., 2009). This interaction provides the necessary co-stimulatory signals for B-cell isotype switching and the generation of memory B-cells and high-affinity IgG antibodies (WHO, 2021).